Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed‐Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin

Ertugliflozin, an inhibitor of sodium‐glucose cotransporter 2, is approved in the United States and European Union for the treatment of type 2 diabetes in adults, both as monotherapy and as part of fixed‐dose combination (FDC) therapies with either sitagliptin or immediate‐release metformin. The eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Sahasrabudhe, Vaishali, Fediuk, Daryl J., Matschke, Kyle, Shi, Haihong, Liang, Yali, Hickman, Anne, Bass, Almasa, Terra, Steven G., Zhou, Susan, Krishna, Rajesh, Dawra, Vikas K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618047/
https://www.ncbi.nlm.nih.gov/pubmed/30427588
http://dx.doi.org/10.1002/cpdd.629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618047/
https://www.ncbi.nlm.nih.gov/pubmed/30427588
http://dx.doi.org/10.1002/cpdd.629

Ejemplares similares